Relay Therapeutics (RLAY) closed at $20.39 on November 9, 2026, up 9.6% from the previous close, on volume of 3,437,030 shares (30-day average 2,537,388).
Data as of November 9, 2026.
9-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Put with Delta Hedge | 19-Mar-27 20 P +23,000 Stock | 500 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Mon, 9-Nov 7:35 AM ET)
TipRanks (Fri, 6-Nov 2:10 PM ET)
TipRanks (Thu, 5-Nov 5:50 PM ET)
Relay Therapeutics: Upcoming Clinical Catalysts Support Newman’s $29 Price Target
TipRanks (Thu, 5-Nov 5:47 PM ET)
Relay Therapeutics (RLAY) Gets a Buy from Barclays
TipRanks (Thu, 5-Nov 3:41 AM ET)
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Wed, 28-Oct 4:12 PM ET)
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Globe Newswire (Tue, 1-Sep 4:46 PM ET)
Relay Therapeutics’ $275 Million Offering: What the Major Capital Raise Signals for RLAY
Market Chameleon (Thu, 21-May 6:32 AM ET)
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Relay Therapeutics trades on the NASDAQ stock market under the symbol RLAY.
As of November 9, 2026, RLAY stock price climbed to $20.39 with 3,437,030 million shares trading.
RLAY has a beta of 1.90, meaning it tends to be more sensitive to market movements. RLAY has a correlation of 0.14 to the broad based SPY ETF.
RLAY has a market cap of $4.47 billion. This is considered a Mid Cap stock.
Last quarter Relay Therapeutics reported $0 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $.03.
In the last 3 years, RLAY traded as high as $21.27 and as low as $1.78.
The top ETF exchange traded funds that RLAY belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
RLAY has outperformed the market in the last year with a price return of +212.3% while the SPY ETF gained +13.4%. RLAY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +3.2% and +12.2%, respectively, while the SPY returned -1.8% and -1.0%, respectively.
RLAY support price is $17.79 and resistance is $19.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLAY shares will trade within this expected range on the day.
